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The MasR receptor (MasR) is an orphan G protein-coupled receptor proposed as a
candidate for mediating the angiotensin (Ang)-converting enzyme 2-Ang-(1–7) protective
axis of renin-angiotensin system. This receptor has been suggested to participate in
several physiological processes including cardio- and reno-protection and regulation
of the central nervous system function. Although the knowledge of the signaling
mechanisms associated with MasR is essential for therapeutic purposes, these are
still poorly understood. Accordingly, in the current study we aimed to characterize
the signaling pathways triggered by the MasR. To do that, we measured cAMP and
Ca2+ levels in both naïve and MasR transfected cells in basal conditions and upon
incubation with putative MasR ligands. Besides, we evaluated activation of ERK1/2 by
Ang-(1–7) in MasR transfected cells. Results indicated the existence of a high degree
of MasR constitutive activity toward cAMP modulation. This effect was not mediated
by the PDZ-binding motif of the MasR but by receptor coupling to Gαi-adenylyl cyclase
signaling pathway. Incubation of MasR transfected cells with Ang-(1–7) or the synthetic
ligand AVE 0991 amplified MasR negative modulation of cAMP levels. On the other
hand, we provided evidence for lack of MasR-associated modulation of Ca2+ levels
by Ang-(1–7). Finally, it was determined that the MasR attenuated Ang-(1–7)-induced
ERK1/2 phosphorylation mediated by AT1R. We provided further characterization of
MasR signaling mechanisms regarding its constitutive activity and response to putative
ligands. This information could prove useful to better describe MasR physiological role
and development of therapeutic agents that could modulate its action.
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INTRODUCTION
The Mas receptor (MasR) is a class A G protein-coupled receptor (GPCR) first described in 1986
because of its ability to transform and induce foci in NIH 3T3 cells and promote tumorigenicity
in nude mice (Young et al., 1986). Currently, it is considered the founding member of the
Mas-related GPCR family (Mrgpr), consisting of∼40 orphan receptors structurally homologous to
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MasR expressed in specific subpopulations of sensory neurons
that detect painful stimuli (Alenina et al., 2008). Although
there has been a lot of information accumulated regarding
its physiological function, based on the multiple criteria used
to recommend the pairing of an orphan receptor with its
cognate ligand, the IUPHAR/BPS Guide to Pharmacology still
considers the MasR as an orphan GPCR (Davenport et al., 2013;
Karnik et al., 2015).
Recently, we provided information that questions the
determination of the endogenous levels of MasR protein through
antibody-based techniques (Burghi et al., 2017). Thus, data from
alternative methods such as mRNA determination appear so
far, as the most solid in terms of MasR tissue distribution and
abundance. In both rats and mice, the highest levels of MasR
mRNA have been found in brain and testis (Young et al., 1988;
Bunnemann et al., 1990; Martin et al., 1992; Metzger et al., 1995;
Alenina et al., 2002). Lower levels of MasR transcripts have also
been detected in heart and kidney (Metzger et al., 1995; Ferrario
et al., 2005; Alenina et al., 2008; Burghi et al., 2017). Noteworthy,
the phenotype of MasR knockout (MasR-KO) mice indicates
that lack of MasR affects behavioral, cardiovascular, renal and
metabolic processes. Both damaging and protective effects have
been reported in MasR-KO mice (Karnik et al., 2015).
The MasR has been proposed as a candidate receptor for
angiotensin (Ang)-(1-7) (Santos et al., 2003; Karnik et al.,
2015), an endogenously produced heptapeptide that belongs to
the renin-angiotensin system (RAS) (Ferrario and Iyer, 1998),
mainly generated through the cleaving action of Ang-converting
enzyme 2 (ACE2) on Ang II (Vickers et al., 2002; Oudit et al.,
2003). Accumulating evidence indicates that the ACE2/Ang-
(1–7) constitute a protective axis of RAS that counterbalances the
pathophysiological effects of overactivation of the classical RAS
axis formed by ACE, Ang II, and Ang II type 1 (AT1) receptor.
Characterization of receptor components of the ACE2/Ang-(1–7
axis is still ongoing (Karnik et al., 2017). There are reports that
have paired MasR with other peptides of the RAS, including
Ang III, Ang IV (Gembardt et al., 2008) and angioprotectin
(Jankowski et al., 2011), but also with the unrelated neuropeptide
FF (Dong et al., 2001).
In many studies, the signaling pathways activated by MasR
have been evaluated using the putative ligand Ang-(1–7). It
has been shown that Ang-(1–7) stimulates arachidonic acid
production in MasR transfected CHO and COS cells (Santos
et al., 2003; Gembardt et al., 2008) and in human mesangial
cells that express MasR (Zimpelmann and Burns, 2009). The
actions of Ang-(1–7) have also been associated to the activation of
mitogen-activated protein kinase (MAPK) p38 (Zimpelmann and
Burns, 2009), modulation of the activity of ERK1/2 (Tallant and
Clark, 2003; Gallagher and Tallant, 2004; Tallant et al., 2005; Su
et al., 2006; Sampaio et al., 2007a; Zimpelmann and Burns, 2009;
Liu et al., 2012), activation of phosphatidylinositol 3-kinase/Akt
pathway (Giani et al., 2007; Sampaio et al., 2007b; Muñoz et al.,
2010), and phospholipase A2 (Santos et al., 2003). Although
the MasR belongs to the superfamily of GPCRs, Ang-(1–7)
failed to produce a conventional G-protein signaling response
as measured by the levels of second messengers like Ca2+, IP3,
and cAMP in MasR transfected cells (Bikkavilli et al., 2006;
Shemesh et al., 2008; Zhang et al., 2012; Tirupula et al., 2014).
On the contrary, conventional G protein signaling has been
reported upon stimulation with NPFF (Dong et al., 2001) and
surrogate ligands (Bikkavilli et al., 2006; Shemesh et al., 2008;
Savergnini et al., 2010; Tirupula et al., 2014). Synthetic non-
peptide ligands of the MasR have been shown to modulate the
Gαq-phospholipase C (PLC) pathway (Zhang et al., 2012).
As the MasR has been suggested to participate in several
physiological processes, definitive elucidation of the signaling
mechanisms involved in triggering its actions is essential to
develop agents that could modulate its function. Accordingly,
the aim of this work was to further characterize the signaling
pathways triggered by the MasR. To do that, we measured cAMP
and Ca2+ levels in both naïve and MasR transfected cells in basal
conditions and upon incubation with putative MasR ligands.
Besides, we evaluated activation of ERK1/2 by Ang-(1–7) in
MasR transfected cells. Results indicated the existence of a high
degree of MasR constitutive activity toward cAMP modulation.
This effect was not mediated by the PDZ-binding motif of the
MasR but by receptor coupling to Gαi-adenylyl cyclase signaling
pathway. Modulation of cAMP levels was also observed after
incubation with Ang-(1–7) and AVE 0991. We also provide
evidence for lack of MasR-associated modulation of Ca2+ levels
by Ang-(1–7). Finally, the MasR attenuated Ang-(1–7) induced
ERK phosphorylation mediated by AT1R.
MATERIALS AND METHODS
Chemicals
Angiotensin-(1-7), cell culture medium, bovine serum albumin
(BSA), isobutyl methylxanthine (IBMX), cAMP, forskolin,
Ang-1-7, FURA-2AM, histamine dihydrochloride, triton X-100,
pertussis toxin and protease inhibitors were obtained from
Sigma Chemical Company (St. Louis, MO, United States).
Fetal calf serum was from Natocor (Argentina). [3H] cAMP,
was purchased from PerkinElmer Life Sciences (Boston, MA,
United States). AVE 0991: 5-formyl-4-methoxy-2-phenyl-
1-[[4-[2-ethylaminocarbonylsulfonamido-5-isobutil-3-thienyl]
phenyl]-methyl]imidazole was obtained from ApexBio
Technology LLC (Houston, TX, United States). Other
chemicals used were of analytical grade and obtained from
standard sources.
Plasmid Constructions
A pcDNA3.1(+)-myc-MasR expression construct corresponding
to the human MasR (accession number: NM_002377.2) fused
to the c-myc tag peptide at N-terminal was acquired from
Life Technologies (Grand Island, NY, United States). An empty
vector [pcDNA 3.1 (+)] was used both as negative control and
to deliver an equal amount of plasmid per transfection in all
the experiments. A pcDNA3.1(+)-myc-MasR-1PDZ expression
construct corresponding to the human MasR, fused to the
c-myc tag peptide at N-terminal, and lacking the last five amino
acids (Val-Glu-Thr-Val-Val) was acquired from Life Technologies
(Grand Island, NY, United States). A pZN-Gαi2 plasmid coding
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for rat Gαi2 was a generous gift from Dr. J. S. Gutkind (Moores
Cancer Center, University of California, San Diego).
Cell Culture and Transfections
HEK293T (human embryonic kidney) and A549 (human
lung carcinoma) cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal calf
serum and 50 µg/ml gentamicin. Cultures were maintained
at 37◦C in humidified atmosphere containing 5% CO2.
For transient transfections, cells were grown to 80–90%
confluency and the cDNA constructs were transfected using
the K2 Transfection System (Biontex, Munich, Germany).
The transfection protocol was optimized as recommended by
the suppliers. Assays were performed 48 h after transfection.
For RNA interference experiments, cells were grown to
80–90% confluency and were cotransfected with pcDNA
3.1 or pcDNA 3.1/myc-MasR plasmids and Non-Targeting
siRNA (UAAGGCUAUGAAGAGAUAC) or human AT1R
siRNA (AUACGUGACUGUAGAAUUG) (100 nM) (Horizon
Discovery Ltd., Cambridge, United Kingdom) using the K2
Transfection System. The transfection protocol was optimized
as recommended by the suppliers. Assays were performed 48 h
after transfection.
Western Blot Assay
In Western blot assays directed to determine ERK1/2
phosphorylation levels, cells were serum starved for 8 h. In
concentration-response assays, cells were incubated with the
indicated concentrations of Ang (1–7) for 5 min; in time-course
experiments, cells were incubated at the indicated periods of
time with Ang (1–7) at a final concentration of either 1.10−10,
1.10−9, or 1.10−7 M. After stimulation cells were washed and
lysed in lysis buffer [1% Triton, 100 mM Hepes, 100 mM
sodium pyrophosphate, 100 mM sodium fluoride, 10 mM EDTA,
10 mM sodium vanadate, 2 mM phenylmethylsulfonyl fluoride
(PMSF) and 0.035 trypsin inhibitory units/ml aprotinin (pH
7.4)] and sonicated to shear DNA. Resulting homogenates
were centrifuged at 15,700 g for 30 min at 15,700 g to remove
insoluble material. Protein concentration in the supernatant was
determined by the BCA assay (Pierce BCA Protein Assay Kit,
Thermo Fisher Scientific, MA, United States). Equal amounts
of proteins were denatured by boiling 5 min in Laemmli buffer
(50 mM Tris–HCl pH 6.8, 2% SDS, 100 mM 2-mercaptoethanol,
10% glycerol and 0.05% bromophenol blue). In Western blot
assays directed to determine MasR protein expression levels,
cells were washed, lysed at room temperature in Laemmli buffer
and sonicated to shear DNA. Heat treatment of samples was
avoided to prevent aggregation of overexpressed MasR. Total
cell lysates were resolved by SDS-PAGE, blotted and incubated
with primary antibodies anti-myc (cat# 2272), anti-pERK1/2
(Thr202/Tyr204) (cat# 9101), anti-ERK1/2 (cat# 9102) (Cell
Signaling Technology, Beverly, MA, United States) or anti-
βtubulin (cat# 6046) (Abcam, Cambridge, MA, United States).
After incubation for 1 h at room temperature with a horseradish
peroxidase-conjugated anti-rabbit antibody (cat# sc-2004) (Santa
Cruz Biotechnology, Santa Cruz, CA, United States), reaction
products were revealed by enhanced chemiluminescence (ECL
Plus, Pierce, Rockford, IL, United States).
cAMP Assay
For determination of cAMP basal levels, transfected cells were
seeded in 12 wells dishes, 24 h later 100% confluent cells were
starved for 2 h and pretreated, when indicated, for 1 h with
pertussis toxin (100 ng/ml) and incubated later for 30 min in
basal culture medium supplemented with 1 mM IBMX at 37◦C.
For time-course assays, transfected cells were seeded in 24 wells
dishes and after 24 h, 100% confluent cells were starved for 2 h
and incubated 5 min in basal culture medium supplemented
with 1 mM IBMX at 37◦C, followed by exposure to 1 µM
forskolin for 5, 10, 15, 30, or 60 min. In concentration response
assays, transfected cells were seeded in 24 wells dishes after
24 h, 100% confluent cells were starved for 2 h and incubated
5 min in basal culture medium supplemented with 1 mM IBMX
at 37◦C, followed by 10 min exposure to 1 µM forskolin to
increase basal cAMP levels, and incubated for 5 min with
indicated concentrations of Ang-(1–7) or AVE 0991. For all
cAMP determinations, the reactions were stopped by ethanol
addition followed by centrifugation at 2,000 g for 10 min. The
ethanol phase was then dried, and the residue resuspended
in 50 mM Tris-HCl pH 7.4, 0.1% BSA. cAMP content was
determined by competition of [3H]cAMP for PKA, as previously
described (Davio et al., 1995).
Cell Proliferation Assay
Cell proliferation was determined by a colorimetric assay
using Cell Titer 96 AQueous Non-Radioactive Cell Proliferation
Assay (Promega, Madison, WI, United States) according to the
manufacturer’s instructions. Transfected cells were seeded at
2.0 × 104 cells/well in a 96-wells plate and incubated in an
atmosphere of 5% CO2 at 37◦C. After incubation for 48 or 72 h,
20 µl of MTS was added to each well and further incubated for
2 h at 37◦C. The absorbance was measured at 490 nm using the
FlexStation 3 microplate reader (Molecular Devices Inc., San Jose,
CA, United States).
Ca2+ Measurements
Changes in intracellular Ca2+ concentration were measured
using fura-2 acetoxymethyl ester (Fura-2AM) fluorescent
indicator. A549 cells were seeded in 96 wells dishes for 24 h
(90–100% confluence). Thereafter, culture media was replaced
by loading buffer (140 mM NaCl, 3.9 mM KCl, 0.7 mM KH2PO4,
0.5 mM Na2HPO4, 1 mM CaCl2, 0.5 mM MgCl2 10 mM glucose,
0.1% BSA, 20 mM HEPES, pH 7.4) containing 4 µM Fura-2AM
and 0.2% pluronic acid and cells were incubated for 90 min at
37◦C in humidified atmosphere containing 5% CO2 to facilitate
the hydrolysis of the ester to the acid form. Excess dye was
removed by washing cells with loading buffer. Fluorescence
was measured in a FlexStation 3 microplate reader (Molecular
Devices Inc., San Jose, CA, United States). The wavelength was
set at 340 and 380 nm, and detection was at 500 nm. After
30 s of initial recording to determine basal levels, 100 nM Ang
(1–7) or 100 µM histamine was added in 100 µl final volumes,
and the time course of intracellular Ca2+ mobilization was
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recorded for 180 s. At the end of the time course, TritonX-100
(0.25% v/v) was added to determine Fmax. Autofluorescence
was quantified by measuring the fluorescence produced by an
equivalent suspension of not-loaded cells. Results were expressed
as the ratio of fluorescence’s 340/380 over basal. Basal levels were
determined as the media of the recorded measurements in the
first 30 s for each well.
RT-PCR and Quantitative RT-PCR
Total RNA was isolated from wild type or transfected HEK293T
cells using Quick-Zol reagent (Kalium Technologies, Bernal,
Argentina) following the manufacturer’s instructions. For
the first-strand cDNA synthesis, 1 µg of total RNA was
reverse-transcribed using the High Capacity cDNA Reverse
Transcription kit (Applied BiosystemsTM, Beverly, MA,
United States) with random primers. Quantitative real-time
PCR (qPCR) was performed in triplicate on the Rotor Gene
Q cycler (Qiagen, Hilden, Germany) using the resulting
cDNA, the HOT FIREPol EvaGreen qPCR Mix Plus (Solis
BioDyne, Tartu, Estonia) for product detection, and the
following primers: human MasR (NM_002377.2) forward,
5′-ATTCCTCATCTTCGCTATGCC -3′ and reverse 5′-
GCAGGGAAATGTGGTGTAGG-3′; human AT1R (M93394.1)
forward, 5′-CCCAAAATTCAACCCTTCCG-3′ and reverse,
5′-CAGAAAAGGAAACAGGAAACCC-3′; human AT2R
(NM_000686.4) forward, 5′-CCCTGAACATGTTTGCAAGC-3′
and reverse 5′-AGGGGTAGATGACAGATTGG-3′; and human
β-Actin forward, 5′-GGACTTCGAGCAAGAGATGG-3′ and
reverse 5′-AGCACTGTGTTGGCGTACAG-3′. The cDNA
was amplified by 45 cycles of denaturing (15 s at 95◦C),
annealing (30 s at 60◦C), and extension (30 s at 72◦C) steps. The
specificity of each primer set was monitored by analyzing the
dissociation curve, and the relative MasR, AT1R or AT2R mRNA
quantification was performed using the comparative 11Ct
method using β-Actin as the housekeeping gene.
Statistical Analysis
Experiments were run as many times as indicated in legends
for figures and data are presented as mean ± standard error of
the mean (SEM). Statistical analysis were carried out by two-
sided Students’ t-test, or one-way- or two-way-ANOVA, followed
by Tukeys’ post test. Post hoc tests were run only if overall
statistically significant difference between means were obtained.
Statistical significance was accepted when P < 0.05. No statistical
differences between variances were observed along the whole
work according to Brown–Forsythe test. All analysis were carried
out with GraphPad Prism 6.00 for Windows, GraphPad Software.
RESULTS
Modulation of Basal cAMP Levels by the
MasR
We initiated the study of the signaling pathways associated
with the MasR by evaluating whether MasR itself modulates
the intracellular levels of cAMP either through the activation
or inhibition of the adenylate cyclase. HEK293T cells were
transfected with different amounts of pcDNA 3.1/myc-MasR
plasmid. Protein expression of MasR increased in response to
increasing amounts of the pcDNA 3.1/myc-MasR plasmid used
for transfections (Figure 1A) and showed an inverse relationship
with accumulated cAMP levels (Figure 1B). Cell viability was not
affected after transfecting cells with the pcDNA 3.1/myc-MasR
plasmid (Figure 1C). Additionally, cAMP was measured after
incubating cells with the adenylate cyclase activator, forskolin, for
various periods of time. Under this experimental condition, cells
that overexpressed the MasR accumulated significantly lower
levels of cAMP compared to control cells (Figure 1D).
The potential participation of the PDZ-binding motif of the
MasR (ETVV) in the regulation of basal cAMP levels was
evaluated by transfecting HEK293T cells with pcDNA 3.1/myc-
MasR or pcDNA3.1/myc-MasR-1PDZ constructs. As shown in
Figure 2A, the ability of the MasR to decrease cAMP levels was
not affected by elimination of the PDZ-binding motif, since the
decrease in cAMP levels detected in cells that expressed the MasR
lacking the PDZ-binding motif was similar to that detected in
cells expressing the wild type MasR.
To investigate the signaling pathways by which the MasR
induced a reduction in cAMP cellular levels, we evaluated
the effect of MasR expression on the accumulation of cAMP
either in the presence of pertussis toxin (PTX) or after co-
expressing the MasR with Gαi2 protein. Pretreatment with PTX
reversed the decrease in cAMP levels associated with MasR
overexpression (Figure 2B) whereas no effect was observed in
cells transfected with the empty vector. As shown in Figure 2C,
overexpression of Gαi2 alone in HEK293T cells caused a slight
decrease in cAMP levels possibly due to its association with
endogenous Gαi-coupled GPCRs. When pcDNA 3.1/myc-MasR
was co-transfected with the pZN-Gαi2 plasmid, cAMP levels
were significantly lower than those obtained after transfecting
with the pcDNA 3.1/myc-MasR plasmid alone and similar to
those obtained with the highest amount of pcDNA 3.1/myc-
MasR employed (0.7 µg/well). No significant differences in
cAMP levels were found between transfecting 0.7 µg/well of
pcDNA 3.1/myc-MasR alone or with pZN-Gαi2 plasmid. Thus,
this condition could indicate the maximal detectable effect of
MasR overexpression over cAMP basal levels (Figure 2C).
MasR Responses to Ang-(1–7) and AVE
0991
The effect of putative MasR ligands on the modulation of
cAMP levels was evaluated using HEK293T cells overexpressing
MasR that were incubated with different concentrations of
either Ang-(1–7) or the synthetic non-peptide ligand AVE 0991
(Figures 3A,B). Incubation with Ang-(1–7) or AVE 0991 led to
a concentration-dependent decrease in the production of cAMP
(pEC50 = 9.18 ± 0.32 and 7.75 ± 0.40, respectively). In cells
transfected with the empty vector, incubation with either ligand
did not alter cAMP levels (Figures 3A,B).
In addition, using a lung carcinoma cell line (A549) that
expresses the MasR endogenously (Gallagher and Tallant,
2004), we investigated whether Ang-(1–7) can modulate the
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FIGURE 1 | Constitutive activity of MasR in HEK293T transfected cells. (A) Analysis of MasR expression by Western Blot. Cells were transfected with the indicated
amounts of a plasmid encoding the c-myc tagged MasR (pcDNA3.1/c-myc-MasR) and cell extracts were resolved by SDS-PAGE and Western Blot using anti-c-myc
antibody. Detection of β-tubulin was used as a protein loading control. Blots were subjected to densitometry analysis using ImageJ software. Data are presented as
mean ± SEM respect to control of at least three independent experiments. Images are representative of at least three independent experiments. Different letters
denote significant difference at p < 0.05. (B) cAMP accumulation. Cells were transfected with the indicated amounts of pcDNA3.1/c-myc-MasR and cAMP levels
were determined after incubation for 30 min with IBMX. 100% corresponds to cAMP levels in cells transfected with mock (pcDNA3.1). Data represent mean ± SEM
of four independent experiments. Different letters denote significant difference at p < 0.05. (C) Cell proliferation. Cells transfected with the indicated amounts of
pcDNA3.1/c-myc-MasR were cultured for 48 h or 72 h. Cell viability was determined by MTS assay and reported as a percent of proliferation respect to mock
transfected cells (n = 3). (D) Time-course production of cAMP. Cells transfected with 0.5 µg/well pcDNA3.1/c-myc-MasR were stimulated during the indicated times
with 1 µM forskolin in the presence of IBMX 1 mM and cAMP levels were determined. Data represent mean ± SEM of three independent experiments. Asterisk
denote significant difference at p < 0.05 by plasmid type within the same time point.
intracellular Ca2+ levels (Figures 3C–F). Incubation with Ang-
(1–7) at 10−7 M concentration did not modify intracellular
Ca2+ levels in A549 cells (Figure 3D). Unlike Ang-(1–7),
histamine (10−4 M) (used as positive control) (Zappia et al.,
2015), originated a significant increase in cytosolic Ca2+ levels
(Figure 3C). To evaluate whether the lack of response to Ang-
(1–7) was a consequence of a low level of endogenous MasR
expression, the same experiments were performed on A549 cells
transfected with the pcDNA 3.1/myc-MasR plasmid. Despite
overexpression of the MasR, stimulation with 10−7 M Ang- (1–7)
did not modify intracellular Ca2+ levels in A549 cells. Under the
same conditions histamine led to an important increase in Ca2+
levels (Figures 3E,F).
Taking into account the relevance of the MAPKs ERK1/2 in
the signaling pathways modulated by GPCRs and considering
that, on this pathway, Ang-(1–7) has been shown to display
opposite actions (Tallant and Clark, 2003; Gallagher and Tallant,
2004; Tallant et al., 2005; Su et al., 2006; Sampaio et al., 2007a;
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FIGURE 2 | Molecular mechanisms of MasR constitutive activity. (A) Effect of deletion of the PDZ- binding motif. Cells were transfected with pcDNA3.1/c-myc-MasR
or a plasmid lacking the last 5 amino acids including the PDZ-binding motif. Basal cAMP levels were determined after 30 min incubation with IBMX. 100%
corresponds to cAMP levels in cells transfected with the empty vector. Data represent mean ± SEM of three independent experiments. Different letters denote
significant difference at p < 0.05. (B) Effect of treatment with pertussis toxin. Basal cAMP levels were determined after 30 min incubation with IBMX in cells treated
with PTX 100 ng/mL or vehicle for 1 h. 100% corresponds to cAMP levels in cells transfected with the empty vector and incubated with vehicle. Data represent
mean ± SEM of four independent experiments. Different letters denote significant difference at p < 0.05. (C) Effect of Gαi overexpression. Cells were transfected
with the indicated amounts of pcDNA3.1/c-myc-MasR and empty vector or 0.3 µg/well of pZN-Gαi2. Basal cAMP levels were determined after 30 min incubation
with IBMX. 100% corresponds to cAMP levels in cells transfected with the empty vector. Data represent mean ± SEM of three independent experiments. Different
letters denote significant difference at P < 0.05.
Zimpelmann and Burns, 2009; Liu et al., 2012), it was of great
interest to study the modulation of ERK1/2 signaling pathway
by this peptide. Thus, in HEK293T cells, we determined the
phosphorylation levels of ERK1/2 in response to incubation
with different concentrations of Ang-(1–7) (Figure 4). In cells
transfected with the pcDNA 3.1/myc-MasR plasmid incubation
with Ang-(1–7) led to a concentration-dependent increase in
ERK1/2 phosphorylation levels. Unexpectedly a similar result
was found in cells that had been transfected with the empty
vector. Suggestively, the presence of the MasR resulted in
lower ERK1/2 activation at every concentration of Ang-(1–7)
analyzed (Figure 4).
Next, we performed a time-response analysis of ERK1/2
phosphorylation levels using three concentrations of Ang-(1–7):
10−10, 10−9, and 10−7 M (Figure 5). Incubation with Ang-(1–
7) at 10−10 and 10−9 M concentration induced similar patterns
of ERK1/2 phosphorylation. At 10−10 and 10−9 M Ang-(1–7),
ERK1/2 phosphorylation peaked at 5 min, decreased and peaked
again at 60 min (Figure 5). In contrast, incubation with a 10−7 M
Ang-(1–7) resulted in a peak of ERK1/2 phosphorylation at
30 min (Figure 5).
At every concentration of Ang-(1–7) analyzed, the presence of
the MasR did not modify the patterns of ERK phosphorylation
obtained. However, in concordance with results shown in
Figure 4, it was evident that in MasR-transfected cells, lower
ERK1/2 phosphorylation levels were attained compared to those
obtained in cells transfected with the empty vector regardless
the concentration of Ang-(1–7) that was present during the
assay (Figure 5).
mRNA Levels of AT1R, AT2R, and MasR
in HEK293T Cells
The levels of mRNA coding for endogenous receptors that
could potentially interact with Ang-(1–7) were determined in
HEK293T cells by qPCR. As shown in Figure 6, HEK293T cells
endogenously express the AT1R. In comparison with AT1R levels,
MasR levels were barely detectable, while the presence of AT2R
mRNA could not be detected. After transfecting HEK293T cells
with pcDNA 3.1/myc-MasR, mRNA levels coding for the MasR
were approximately 30,000 times higher than that encoding for
the AT1R. There was no apparent modification in AT1R mRNA
levels after transfection with the myc-MasR plasmid (Figure 6A).
Participation of MasR and AT1R in
Ang-(1–7) Induced ERK1/2
Phosphorylation
To evaluate the possible participation of the AT1R in Ang-(1–
7)-induced ERK1/2 activation, we silenced the expression of this
receptor in HEK293T cells using an AT1R siRNA (Figure 6B).
After 48 h of transfection, the mRNA levels of AT1R were ∼50%
lower in AT1RsiRNA-transfected cells as compared to those
transfected with scrambled siRNA (Figure 6B).
In concordance with results shown in Figure 4, in cells
cotransfected with the empty vector and scrambled siRNA,
incubation with 10−9 and 10−7 M Ang-(1–7) for 5 min led to a
significant increase in ERK1/2 phosphorylation levels compared
to the basal value. Cotransfection of pcDNA 3.1/myc-MasR
with scrambled siRNA resulted in lower ERK1/2 activation
at both concentrations of Ang-(1–7) analyzed (Figure 6C).
However, after silencing the AT1R, no response to Ang-(1–
7) was observed. Ang-(1–7)-induced ERK1/2 phosphorylation
levels attained under these conditions were similar to those
obtained after incubation with vehicle regardless the plasmid that
was used for transfection (Figure 6C).
DISCUSSION
To date, more than 100 GPCRs have no known endogenous
or natural exogenous ligands, suggesting that many biological
Frontiers in Pharmacology | www.frontiersin.org 6 February 2019 | Volume 10 | Article 146
fphar-10-00146 February 20, 2019 Time: 17:16 # 7
Burghi et al. Mas Receptor Signaling
FIGURE 3 | Effect of Ang-1–7 and AVE 0991 on cAMP and Ca2+ levels in MasR-expressing cells. Cells transfected with pcDNA3.1/c-myc-MasR or pcDNA3.1 were
incubated with increasing concentrations of Ang-(1–7) (A) or AVE 0991 (B) in presence of 1 mM IBMX and 1 µM FSK. The levels of cAMP were determined after
5 min 100% corresponds to basal levels of cAMP. Data represent mean ± SEM of three independent experiments. Variation of the intracellular Ca2+ concentration in
A549 cells in response to Ang-(1–7). A549 cells with endogenous expression of MasR (C,D) or transfected either with the empty pcDNA 3.1 vector (E) or with the
pcDNA 3.1/myc-MasR vector (F) were placed in 96-well plates 24 h before the experiment. Cells were incubated with FURA 2-AM, washed and stimulated with
Histamine 10-4 M (positive control) and Ang-(1–7) 10-7 M (C–F). Arrows indicate addition of the stimulus. Fluorescence determinations were performed as described
in Section “Materials and Methods.” Results are representative of three independent experiments.
functions of these receptors are still unknown. These orphan
GPCRs have immense therapeutic potential, since ∼30% of
all clinically relevant drugs modulate the activity of GPCRs
or related signaling pathways (Solinski et al., 2014; Fang et al.,
2015; Hauser et al., 2018). Particularly for MasR, numerous
studies have attributed a role for this receptor in the regulation
of cardiovascular, renal and central nervous system (CNS)
function (Karnik et al., 2015). However, the intracellular
signaling pathways activated by MasR remain insufficiently
characterized, preventing definitive knowledge of ligand/
receptor pharmacology.
In the current study, we analyzed whether the MasR is
capable of modulating the intracellular levels of cAMP in the
absence of an external stimulus. In order to determine the
constitutive activity of the MasR we increased the number
of receptors expressed by varying the amount of the pcDNA
3.1/myc-MasR plasmid used in the transfections. The decrease
in cAMP basal levels associated with the increased MasR
expression indicated that MasR possesses constitutive activity
toward negative modulation of cAMP levels. Moreover, this
was also detected by the addition of the activator of adenylate
cyclase forskolin. The decrease in cAMP accumulation in basal
conditions and/or stimulated by forskolin has been reported in
studies of constitutive activity of GPCRs that are coupled to
Gαi/o proteins (Seifert and Wenzel-Seifert, 2002) or that form
complexes with proteins with PDZ domains (Broselid et al.,
2014). Recently, the interaction of the c-terminal binding motif
of the MasR with PDZ domains of different proteins has been
reported (Tirupula et al., 2015). Considering this, we explored
whether signaling pathways involving Gαi/o proteins and/or
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FIGURE 4 | Dose-response effect of Ang-(1–7) on ERK1/2 phosphorylation
levels. HEK293T cells were transfected either with the pcDNA3.1/myc-MasR
vector or with the empty vector (pcDNA 3.1), starved in DMEM without serum
for 8 h and then incubated for 5 min with increasing concentrations of
Ang-(1–7). (A) Phosphorylation levels of ERK1/2 at activating residues
Thr202/Tyr204, total ERK1/2 and β-tubulin abundance were determined by
Western Blotting. (B) Data quantification. Bands intensity was quantified by
optical densitometry, each individual value of pERK was normalized to that of
total ERK and expressed as relative to the value obtained after incubation with
cells transfected with pcDNA 3.1 and incubated with vehicle (basal value).
Data are means ± SEM of three independent experiments. Values were fitted
to a sigmoidal dose-response curve. Maximal response best-fitted values
were analyzed by extra sum-of-squares F test, significantly different
(P < 0.001).
PDZ domains are associated with MasR and could lead to a
decrease in cAMP levels. Lack of involvement of the PDZ-
binding motif in the constitutive activity of the MasR in terms
of inhibition of cAMP levels is in agreement with a recent work
in which deletion of this motif did not modify the constitutive
activity of MasR in terms of stimulation of inositol-1-phosphate
pathway (Tirupula et al., 2015). Possibly proteins with PDZ
domains are involved only in regulating the ubiquitination and
degradation of the MasR (Bian et al., 2013).
Given that PTX not only prevents the stimulation of Gαi/o
proteins by GPCRs bound to agonists, but also that exerted
by those free of ligands, it is a very useful tool to highlight
the constitutive activity of many GPCRs (Seifert and Wenzel-
Seifert, 2002). Thus, the reversal of the decrease in cAMP levels
obtained by preincubating the cells overexpressing MasR with
PTX suggested that this effect is mediated by Gαi/o proteins. In
addition, it was shown that the concomitant overexpression of the
Gαi2 protein caused a greater decrease in basal cAMP levels. By
modifying the stoichiometry of other of the components of the
system, in this case, by increasing the Gαi2 protein expression
levels, we facilitated receptors to reach active conformations
coupled to the G protein by which they signal. This gives further
support to the MasR having constitutive activity. In all, these
results indicated that in the absence of an external stimulus, MasR
is capable of coupling and activating the Gαi protein with the
consequent decrease in cAMP levels. Previous studies reported
that MasR constitutively activates Gαq and Gα11 proteins (Canals
et al., 2006; Zhang et al., 2012; Tirupula et al., 2014). In the
same system, Tirupula et al. (2014) also reported constitutive
coupling of MasR to Gα12 and even Gαs proteins. Interestingly,
compound AR234960, reported as an agonist for the Gαq-
mediated pathway, was shown to decrease cAMP levels (Zhang
et al., 2012; Tirupula et al., 2014).
The physiological relevance of the constitutive activity of the
MasR remains to be determined. Constitutive activity of GPCRs
for various neurotransmitters contributes to basal neuronal
activity (Seifert and Wenzel-Seifert, 2002). The mRNA encoding
the MasR has been detected in various regions of the rat and
mouse brain (Young et al., 1988; Bunnemann et al., 1990;
Martin et al., 1992; Metzger et al., 1995). In addition, it has
been reported that MasR-KO mice have alterations of the CNS
(Walther et al., 1998, 2000a,b). Thus, the constitutive activity
of the MasR could play a regulatory role in this system. In
addition, when analyzing the control of cardiac function by
the autonomous system, it has been hypothesized that the Gαi
protein could have a cardioprotective role (Foerster et al., 2003).
MasR mRNA has been detected in rat and mouse heart (Metzger
et al., 1995; Ferrario et al., 2005; Alenina et al., 2008; Burghi
et al., 2017) and the phenotype of MasR-KO mice includes
cardiac dysfunction (Santos et al., 2006; Gava et al., 2012).
Thus, the constitutive activation of the Gαi protein mediated by
the MasR may have a role in MasR-mediated cardioprotection.
However, when interpreting the in vivo data, the contribution
of Ang-(1–7) and other ligands cannot be ruled out. Indeed, the
pathophysiological relevance of Ang-(1–7) in the heart has been
highlighted by studies demonstrating that Ang-(1–7) can reduce
or prevent cardiac remodeling by decreasing hypertrophy and
fibrosis (Benter et al., 2006; Grobe et al., 2007). Additionally,
several studies demonstrated that Ang-(1–7) exerts a protective
effect against cardiac ischemia-induced injury and arrhythmias
(Ferreira et al., 2001; De Mello, 2004). Moreover, given the
beneficial effects obtained in heart dysfunction with either the
orally active non-peptide compound AVE 0991 (Ferreira et al.,
2007) or the surrogate ligand CGEN-856S (Savergnini et al.,
2013), potential therapeutic applications of the findings obtained
with Ang-(1–7) have been reinforced.
It is important to highlight the relevance of detecting the
constitutive activity of orphan GPCRs, e.g., the MasR, as it
allows posterior evaluation of the response of various ligands,
putative or new, endogenous or synthetic, and with different
efficacy, i.e., not only agonists and antagonists but also inverse
agonists. This greatly contributes to the study of the MasR
function(s) even in the absence of definitive knowledge of its
endogenous ligand.
The decrease in cAMP levels in a concentration-dependent
manner observed after incubation with Ang-(1–7) or AVE 0991
in MasR-overexpressing cells indicates that these ligands can act
as MasR agonists for this signaling response. The absence of
modulation of cAMP in the control cells agrees with the lack of
significant expression levels of endogenous MasR and indicated
that none of these ligands was able to activate this signaling
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FIGURE 5 | Kinetics of Ang-(1–7)-induced ERK1/2 phosphorylation. HEK293T cells transfected as described in Figure 4, were incubated with Ang-(1–7) at the
different concentrations indicated for the indicated periods. Phosphorylation levels of ERK1/2, total ERK1/2, and β-tubulin were determined by Western Blotting.
Phosphorylation of ERK1/2 was normalized to that of total ERK1/2 and expressed as relative to the value obtained at 0 min in cells transfected with the empty vector
(pcDNA 3.1). Data represents the mean ± SEM of three independent experiments. ∗P < 0.05 by plasmid type within the same time point.
pathway by binding to other endogenous receptors present in
HEK293T cells.
Angiotensin-(1–7) has been reported to interact with the
AT1R (Gironacci et al., 1999; Galandrin et al., 2016; Teixeira et al.,
2017). Some of its actions appear to require the participation
of the AT1R (Jaiswal et al., 1991; Osei et al., 1993; Garcia and
Garvin, 1994; Galandrin et al., 2016; Teixeira et al., 2017), the
AT2R (De Souza et al., 2004; Walters et al., 2005; Shimada
et al., 2015) or both (Jaiswal et al., 1992; Gironacci et al.,
1994). Since HEK293T cells endogenously express AT1R it
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FIGURE 6 | Participation of the MasR and AT1R in Ang-(1–7) induced ERK phosphorylation. (A) Levels of mRNA coding for AT1R and MasR in HEK293T cells. The
levels of mRNA were determined by qPCR in HEK293T cells transfected with pcDNA 3.1 and pcDNA 3.1/myc-MasR vectors as described in Section “Materials and
Methods.” Data represent the mean ± SEM of three independent experiments. (B) Levels of mRNA coding for AT1R in cells transfected with AT1R siRNA. HEK293T
cells were transfected with scrambled siRNA or AT1R siRNA and after 48 h the mRNA levels coding for AT1R were determined by qPCR as described in Section
“Materials and Methods.” Data represent the mean ± SEM of three independent experiments. (C) Effect of silencing the AT1R on Ang-(1–7)-induced activation of
ERK1/2. HEK293T cells that were transfected with the pcDNA3.1/myc-MasR plasmid or with the empty vector (pcDNA 3.1), were incubated for 5 min with
Ang-(1–7) at the indicated concentrations. Experiments were performed in AT1R-silenced cells and in control cells (scrambled siRNA). Phosphorylation levels of
ERK1/2 at activating Thr202/Tyr204, total ERK1/2 and β-tubulin abundance were determined by Western Blotting. Bands intensities were quantified by optical
densitometry, pERK individual values were normalized to total ERK1/2 values and expressed as relative to the value obtained with control cells (transfected with
pcDNA 3.1 and scramble siRNA) and incubated with vehicle (basal value). Data are means ± SEM of three independent experiments. Different letters denote
significant difference at P < 0.05.
was hypothesized that Ang-(1–7) could potentially modulate
G proteins associated with AT1Rs. However, this was not the
case. Our observations are in good correlation with previous
reports showing that stimulation of HEK293T cells with Ang-(1–
7) does not activate G proteins through endogenously expressed
receptors (Galandrin et al., 2016; Teixeira et al., 2017). Although
it was reported that Ang-(1–7) could bind to AT1Rs and promote
the recruitment of β2-arrestin in HEK293T cells overexpressing
AT1Rs, this interaction did not show efficacy toward modulation
of G protein-mediated pathways (Galandrin et al., 2016;
Teixeira et al., 2017).
Recently, Gaidarov et al. (2018) reported no change in
forskolin-stimulated cAMP levels after incubation with Ang-(1–
7) or AVE 0991 in MasR-transfected HEK293 cells whereas the
small synthetic molecule AR234958 was shown to elicit a dose-
dependent reduction of forskolin-stimulated cAMP in the same
cells. On the contrary, we detected a decrease in cAMP levels in a
concentration-dependent manner after incubation with Ang-(1–
7) and AVE 0991. The reasons for this discrepancy could rely on
the different incubation times used to detect the cAMP levels. As
compared to the study of Gaidarov et al. (2018), pre-incubation
of cells with forskolin was done for 10 min (instead of 30 min)
and incubation with ligands in the presence of forskolin was done
for 5 min (instead of 60 min). We designed and performed our
experiments to detect the modulation of cAMP levels elicited
by Ang-(1–7) and AVE 0991 after incubation for short periods
of time to prevent as much as possible the proteolysis of Ang-
(1–7). This experimental design also aimed at avoiding the
mechanisms that tend to return the intracellular cAMP levels to
basal values and the attenuation mechanisms of GPCRs signaling
that could occur when incubating for longer periods of time.
Finally, the cells were exposed to a moderate concentration of
forskolin (1 µM) for a total time of 15 min (instead of 90 min)
in order to avoid overstimulation of adenylyl cyclase reaching
extremely high cAMP levels that could mask the reduction of
this second messenger levels elicited by these ligands. This is of
relevance considering that Ang-(1–7) and AVE 0991 may display
lower efficacy than the synthetic ligand AR234958 toward this
signaling pathway.
In contrast to our current results, incubation with Ang-(1–7)
has been reported to increase cAMP levels in human umbilical
vein endothelial cells, kidney mesangial cells, aortic vascular
smooth muscle cells and in HEK293 cells overexpressing Mas
or MrgD receptors (Tetzner et al., 2016). The latter response
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was blocked by D-Ala7-Ang-(1–7) and D-Pro7-Ang-(1–7); was
also reduced in MasR- or MrgD- deficient cells and blunted
in MasR/MrgD double knockout cells (Tetzner et al., 2016).
The reasons for this discrepancy could rely on the different
approaches used to detect the cAMP levels. We designed and
performed our experiments in order to determine total cAMP
cellular levels and not only the intracellular ones. This is of
relevance since the intracellular regulation of cAMP depends not
only on the balance between its production by adenylyl cyclase
and its degradation by phosphodiesterases, but also on the efflux
of cAMP through members of the multidrug associated resistance
protein family (Carozzo et al., 2015).
Under the analyzed conditions, it was evident that Ang-(1–7)
was not capable of activating the Gαq-PLC signaling pathway
that leads to an increase in intracellular Ca2+ levels. Current
results agree with previous reports that showed that unlike the
effect exerted by synthetic MasR agonists, Ang-(1–7) appears not
to modulate this pathway (Bikkavilli et al., 2006; Shemesh et al.,
2008; Zhang et al., 2012; Tirupula et al., 2014).
The modulation of the activity of ERK1/2 by Ang-(1–7)
has been analyzed previously. Several studies reported that this
heptapeptide antagonizes the stimulation of ERK1/2 induced
by various agents, such as bovine fetal serum (Gallagher and
Tallant, 2004; Tallant et al., 2005), Ang II (Tallant and Clark,
2003; Su et al., 2006; Sampaio et al., 2007a), advanced glycated
end products and TGF-β (Alzayadneh and Chappell, 2014).
Additionally, some studies reported that Ang-(1–7) induced a
direct activation of ERK1/2 (Zimpelmann and Burns, 2009; Liu
et al., 2012). Participation of the MasR in these effects was
suggested through the use of either antisense oligonucleotides for
the receptor (Tallant et al., 2005), or the peptide D-Ala7-Ang-(1–
7) (Su et al., 2006; Zimpelmann and Burns, 2009; Liu et al., 2012;
Alzayadneh and Chappell, 2014). Our current observation that
Ang-(1–7) caused an increase in the levels of phosphorylation of
ERK1/2 both in cells that overexpressed the MasR and in control
cells made it necessary to evaluate the endogenous expression
of other receptors that could bind Ang-(1–7) in HEK293T cells.
Because in control cells expression of AT2R was not detected and
the endogenous expression of MasR was negligible in comparison
with AT1R, it was possible that the latter was mediating the
activation of ERK1/2 by Ang-(1–7). Lack of ERK1/2 activation
induced by Ang-(1–7) in HEK293T cells whose AT1R expression
was silenced indicated that this receptor was implicated in this
response. On the other hand, the absence of response to Ang-
(1–7) observed in HEK293T cells overexpressing MasR whose
AT1R expression was silenced indicated that MasR alone was not
involved in increasing phosphorylated ERK levels. Altogether,
these results indicate that the attenuation of the response
observed by overexpressing the MasR both in the concentration-
response and in time-response analysis are a consequence of
MasR ability to attenuate ERK activation induced by Ang-(1–
7) over the AT1R. In this sense, it has been reported that the
MasR acts as a physiological antagonist of the AT1R since it was
observed that the coexpression of both receptors in CHO-K1
cells significantly decreased both the Ang II-induced production
of IP1 and the increase of intracellular Ca2+ levels mediated by
the AT1R (Kostenis et al., 2005). The mechanism behind this
modulation could be the formation of MasR-AT1R heterodimers
(Kostenis et al., 2005).
The analysis of the interaction between Ang-(1–7) and the
AT1R originated discrepancies. Angiotensin-(1–7) has been
found to compete with Ang II with either high (Gironacci
et al., 1999) or low affinity (Rowe et al., 1995; Clark et al.,
2001), while lack of competition was also reported (Bosnyak
et al., 2011). Recently, Galandrin et al. (2016) by performing
direct competition binding studies on membranes from AT1R–
expressing HEK293T cells reported that Ang-(1–7) displaced
Ang II with a Ki of 360 nM. In addition, Teixeira et al. (2017)
by performing competition binding assays using 3H-Ang II
in HEK293T cells transfected with AT1R reported that Ang-
(1–7) binds to the AT1R yielding an affinity of ∼200 nM. We
performed ERK1/2 phosphorylation assays in HEK293T cells
FIGURE 7 | Proposed MasR signaling mechanisms. The MasR has constitutive activity toward reduction of cAMP levels. This effect is mediated by receptor coupling
to Gαi adenylyl cyclase signaling pathway. MasR putative ligands [Ang-(1–7) and AVE 0991] amplify MasR activity. In addition to modulation of cAMP, the MasR
attenuates Ang-(1–7)-induced ERK1/2 phosphorylation mediated by AT1R.
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endogenously expressing AT1R and barely detectable MasR levels
using wild type cells and in conditions where MasR levels were
very high. On the contrary, binding experiments in HEK293T
cells were performed after overexpressing AT1R. The reasons
for the differences between bindings results and the apparent
high affinity of Ang-(1–7) in our results of ERK phosphorylation
assays could be due to different relative expression levels of
receptors that belong to the RAS (MasR, AT1R) that may
influence Ang-(1–7) binding affinity given the pluridimensional
action of Ang-(1–7) on different RAS receptors (Galandrin
et al., 2016; Teixeira et al., 2017). Although the use of a system
overexpressing a receptor is a useful tool to examine direct
interactions with ligands, this may not be representative of the
function of the receptor in its natural environment. In agreement
with our results, Gaidarov et al. (2018) reported that in rat
aortic endothelial cells (RAEC), a common source of endogenous
rat angiotensin receptors, Ang-(1–7) inhibited the more potent,
picomolar phase of Ang II-induced ERK1/2 phosphorylation at
concentrations much lower than values obtained in presence
of recombinant AT1 receptors. These authors postulated that
in RAEC, angiotensin receptors may be organized in higher
order signaling complexes with other receptors and signaling
molecules, i.e., signalosomes, which may have higher affinities
for Ang-(1–7) and that this higher order organization may not
be present in recombinant cells or may be disturbed (Gaidarov
et al., 2018). Finally, since the renal AT1R found on proximal
tubules has very high affinity for Ang II (in the pM range) it
is possible that in HEK293T cells, AT1R affinity is shifted to
the left for both Ang II and Ang-(1–7). In this sense, Garcia
and Garvin (1994) reported that Ang-(1–7) has a biphasic effect
on transport, increasing fluid and bicarbonate absorption in the
rat proximal straight tubule at 10−12 M concentration, while at
10−8 M concentration, Ang-(1–7) was found to decrease fluid
absorption. Of note, both effects were blocked by losartan.
In glomerular mesangial cells, Ang-(1–7) has been shown
to induce ERK1/2 through a MasR-mediated mechanism with
no apparent participation of either AT1R or AT2R (Liu et al.,
2012). The discrepancy between this study and current results
could be due to the type of cells employed. For example,
AT2R mRNA has been detected in mesangial cells (Tetzner
et al., 2016) while we could not detect AT2R expression in
HEK293T cells. Thus, in mesangial cells, a likely MasR-AT2R
heterodimerization (Patel and Hussain, 2018) could contribute
to Ang-(1–7) stimulation of ERK via MasR. Finally, the different
levels of receptors attained under physiological conditions (Liu
et al., 2012) versus the MasR overexpressing conditions used in
the current study should be considered as a potential contributing
factor to observed differences.
In summary, using an in vitro system, we demonstrated that
human MasR has constitutive activity toward reduction of cAMP
levels. We provided evidence in support for participation of
Gαi2 protein in this effect. Incubation with putative ligands,
either natural [Ang-(1–7)], or synthetic (AVE 0991), amplified
this activity associated with MasR. In addition to modulation
of cAMP, the MasR was shown to attenuate Ang-(1–7) induced
ERK1/2 phosphorylation mediated by AT1R. We also provided
evidence for lack of MasR-associated modulation of Ca2+ levels
by Ang-(1–7) (Figure 7). This information could prove useful
to better describe MasR physiological role and development of
therapeutic agents that could modulate its action.
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